HYPERTENSION- THE LATEST MANAGEMENT
Dr. Awadhesh kumar sharma is a young, diligent and dynamic interventional cardiologist. He did his graduation from GSVM Medical College Kanpur and MD in Internal Medicine from MLB Medical college jhansi. Then he did his superspecilisation degree DM in Cardiology from PGIMER & DR Ram Manoher Lohia Hospital Delhi. He had excellent academic record with Gold medal in MBBS,MD and first class in DM.He was also awarded chief ministers medal in 2009 for his academic excellence by former chief minister of UP Smt Mayawati in 2009.He is also receiver of GEMS international award.He had many national & international publications.He is also in editorial board of international journal- Journal of clinical medicine & research(JCMR).He is also active member of reviewer board of many journals.He is also trainee fellow of American college of cardiology. He is currently working in NABH Approved Gracian Superspeciality Hospital Mohali as Consultant Cardiologist.
In the NOACs era , how to deal with liver cirrhosis needing anticoagulation?magdy elmasry
Is My Cirrhotic Patient Auto-anticoagulated?
Does "Auto-anticoagulation" Protect Against thrombosis in Patients with Liver Disease?
The normal balance of hemostasis and rebalanced hemostasis in liver disease.Should we anti-coagulate patients with cirrhosis?How safe is anticoagulation therapy to use in those with chronic liver disease?
HYPERTENSION- THE LATEST MANAGEMENT
Dr. Awadhesh kumar sharma is a young, diligent and dynamic interventional cardiologist. He did his graduation from GSVM Medical College Kanpur and MD in Internal Medicine from MLB Medical college jhansi. Then he did his superspecilisation degree DM in Cardiology from PGIMER & DR Ram Manoher Lohia Hospital Delhi. He had excellent academic record with Gold medal in MBBS,MD and first class in DM.He was also awarded chief ministers medal in 2009 for his academic excellence by former chief minister of UP Smt Mayawati in 2009.He is also receiver of GEMS international award.He had many national & international publications.He is also in editorial board of international journal- Journal of clinical medicine & research(JCMR).He is also active member of reviewer board of many journals.He is also trainee fellow of American college of cardiology. He is currently working in NABH Approved Gracian Superspeciality Hospital Mohali as Consultant Cardiologist.
In the NOACs era , how to deal with liver cirrhosis needing anticoagulation?magdy elmasry
Is My Cirrhotic Patient Auto-anticoagulated?
Does "Auto-anticoagulation" Protect Against thrombosis in Patients with Liver Disease?
The normal balance of hemostasis and rebalanced hemostasis in liver disease.Should we anti-coagulate patients with cirrhosis?How safe is anticoagulation therapy to use in those with chronic liver disease?
Management of hypertensive condition in 2020 according to AHA/ASA guidelines. We will discuss the presentation, clinical assessment, investigations, and management of hypertension along with major randomized controlled trials and guidelines.
Latest definition of sepsis, application of qSOFA, latest evidence on treatment of septic shock,role of fluids, role of steroids, isobalance salt solution
Management of hypertensive condition in 2020 according to AHA/ASA guidelines. We will discuss the presentation, clinical assessment, investigations, and management of hypertension along with major randomized controlled trials and guidelines.
Latest definition of sepsis, application of qSOFA, latest evidence on treatment of septic shock,role of fluids, role of steroids, isobalance salt solution
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Marcellus Simadibrata Kolopaking MD PhD
Department of Medical Education
Division Gastroenterology Department of Internal Medicine
Faculty of Medicine University Indonesia
Dr.Cipto Mangunkusumo Hospital Jakarta
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
2. STRESS-RELATED MUCOSAL INJURY
Stress-related mucosal injury is a term used to
describe erosions in the gastric mucosa that
occur in almost all patients with acute, life-
threatening illness .
3. Stress ulcers are diffuse in nature and
are not amenable to endoscopic
therapy; they generally heal over time,
without intervention, as the patient’s
clinical status improves.
4. These erosions can be superficial and confined
to the mucosa, or they can bore deeper and
extend into the submucosa.
The deeper lesions are called stress ulcers,
and are more likely to cause troublesome
bleeding.
The term “stress ulcer” will indicate both
types of gastric erosions.
5. Stress Ulcers Peptic Ulcers
Multiple
superficial
lesions at the
proximal
stomach bulb;
involves
superficial
capillaries
Few deep
lesions in the
duodenum;
typically
involves a
single vessel
6. Pathogenesis
The gastric mucosa must protect itself against injury
from the acid environment in the stomach, and
gastric mucosal blood flow is considered to play
an important part in this protection (by supplying
nutrients to maintain the functional integrity of
the mucosa).
The importance of mucosal blood flow is
demonstrated by the fact that 70 to 90% of the
blood supply to the stomach is delivered to the
gastric mucosa .
7. Splanchnic vasoconstriction and hypoperfusion
is common in critically ill patients, and the
resultant decrease in gastric mucosal blood
flow is considered the principal cause of
gastric erosions .
Once the gastric mucosa is disrupted, the
acidity in the gastric lumen can aggravate
the surface lesions.
8. Clinical Consequences
Erosions are visible on luminal surface of the
stomach in 75% to 100% of patients within
24 hours of admission to the ICU .
These lesions often ooze blood from eroding into
superficial capillaries, but clinically significant
bleeding (i.e., results in a significant drop in
blood pressure or a drop in hemoglobin >2 g/dL) is
observed in less than 5% of ICU patients .
9.
10.
11. Risk Factors
The independent risk factors (i.e., require no
other risk factors to promote bleeding)
include mechanical ventilation for longer than
48 hours, and a significant coagulopathy
(i.e., platelets <50,000, INR>1.5, or activated
PTT>twice control) .
However, all of the conditions are indications
for prophylaxis to prevent stress ulcer
bleeding.
12. Preventive Measures
The goal of prophylaxis for stress ulcers is not
to prevent their appearance (since they
appear almost immediately after ICU
admission), but to prevent clinically
significant bleeding from these lesions.
13. Surveys indicate that about 90% of ICU
patients receive some form of prophylaxis for
stress ulcer bleeding , but this is excessive.
Prophylaxis is primarily indicated for the
conditions listed in Table , and is especially
important for patients who are ventilator-
dependent for longer than 48 hours, or have
a significant coagulopathy.
14. Methods of Prophylaxis
The principal method of prophylaxis for stress ulcer
bleeding is to block the production of gastric
acid using histamine type-2 receptor antagonists
or proton pump inhibitors, and maintain a pH≥4
in gastric aspirates.
The other method of prophylaxis involves the use of a
cytoprotective agent (sucralfate) that protects
damaged areas of the gastric mucosa without
altering gastric acidity .
15. Antacids
a. Dose-dependent neutralization of gastric
acid .
b. Not recommended for routine use because
of frequency of administration
(up to every hour).
Adverse effects (diarrhea, constipation,
electrolyte abnormalities), and interactions
(interferes with the absorption of some
drugs)
16.
17. Histamine H2- Receptor Antagonists
Inhibition of gastric acid secretion with histamine
H2-receptor antagonists (H2 blockers) is the
most popular method of stress ulcer
prophylaxis.
The drugs most frequently used for this purpose
are ranitidine and famotidine; both drugs
are typically given as an intravenous bolus .
Ranitidine is the most studied gastric
acid–suppressing drug for stress ulcer
prophylaxis..
18. A single 50 mg dose of ranitidine given as an IV
bolus will reduce gastric acidity (pH>4) for 6–8
hrs, so the typical ranitidine dosing regimen is
.
Famotidine has a longer duration of action;
i.e., a single 20 mg dose of famotidine given as an
IV bolus will reduce gastric acidity (pH>4) for
10–15 hours , so the typical famotidine dose
50 mg IV every 8
hours
20 mg IV every 12
hours
19. DOSE ADJUSTMENTS:
Intravenous doses of famotidine and
ranitidine are largely excreted unchanged in
the urine, and accumulation of these drugs in
renal failure can produce a neurotoxic
condition characterized by confusion,
agitation and even seizures.
Reduced dosing is therefore advised in patients
with renal insufficiency.
20.
21. BENEFITS AND RISKS:
H2 blockers are effective in reducing the
incidence of clinically important bleeding from
stress ulcers, but the benefit occurs primarily in
patients with one or more of the risk factors.
Prolonged use of H2 blockers is accompanied by a
decrease in their ability to maintain a pH ≥4 in
gastric aspirates, but this does not influence
their ability to prevent stress ulcer-related
bleeding .
22. The principal risks associated with H2 blockers
are related to reduced gastric acidity , these
risks include an increased in-cidence of
infectious
These risks, however, may be greater with PPI .
gastroenteriti
s
pneumonia
Clostridium difficile
enterocolitis
from aspiration of
infectious gastric
secretions into the
airways
23. Proton Pump Inhibitors (PPIs)
Proton pump inhibitors (PPIs) are potent acid-
suppressing drugs that reduce gastric acidity
by binding to the membrane pump responsible
for hydrogen ion secretion by gastric parietal
cells .
24. These drugs are actually prodrugs, and must
be converted to the active form within
gastric parietal cells.
Once activated, these drugs bind irreversibly
to the membrane pump and produce complete
inhibition of gastric acid secretion.
25. PHARMACOLOGICAL
ADVANTAGES
PPIs have several advantages over H2 blockers.
First, they produce a greater reduction in
gastric acidity and have a longer duration
of action, often requiring only a single daily
dose.
26. Secondly, the responsiveness to PPIs
does not diminish with continued
usage .
Finally, PPIs are metabolized in the liver,
and do not require a dose adjustment in
renal failure.
As a result of these advantages, PPIs are
gradually replacing H2 blockers for stress
ulcer prophylaxis in hospitalized patients .
27.
28. COMPARATIVE BENEFITS AND RISKS:
Despite their enhanced potency, PPIs have not
shown any advantage over H2 blockers for
prophylaxis of stress ulcer bleeding .
Furthermore, the enhanced gastric acid
suppression with PPIs may create a greater
risk of infection than with H2 blockers.
PPIs may also have immunosuppressive
effects through the inhibition of
neutrophils.
29. This is supported by studies showing a higher
incidence of hospital-acquired pneumonia
with PPIs compared to H2 blockers , and a
higher incidence of Clostridium difficile
enterocolitis in outpatients treated with PPIs
instead of H2 blockers .
The overall risk-benefit accounting for PPIs is
in favor of avoiding these drugs for the
prophylaxis of stress ulcer bleeding.
30. PPIS AND CLOPIDOGREL
The popular antiplatelet agent, clopidogrel, is
a prodrug that is converted to its active form by
the same (cytochrome P-450 2C19) pathway
in the liver that metabolizes PPIs.
Therefore, PPIs can impede clopidogrel
activation in the liver(by competitive
inhibition) and reduce its antiplatelet activity .
31. This effect is evident with in vitro tests of
platelet aggregation, but the clinical
significance of this interaction is unclear.
Nevertheless,the Food and Drug
Administration advises avoiding PPIs, if
possible, in patients taking clopidogrel.
32.
33. Sucralfate
Sucralfate is an aluminum salt of sucrose
sulfate that adheres primarily to damaged
areas of the gastric mucosa (via electrostatic
bonds with exposed proteins) and forms a
viscous covering that shields the denuded
surface from luminal acids and pepsin
proteolysis.
34. It is classified as a protectant or
cytoprotective agent , and has no effect on
gastric acid secretion.
Sucralfate promotes the healing of gastric and
duodenal ulcers, and reduces the incidence of
clinically important bleeding from stress ulcers .
35. Sucralfate is available as atablet (1 gram per
tablet) or a suspension (1g/10 mL), and is
most effective when given as a suspension
(tablets can be crushed and dissolved in
water, if necessary).
A single dose of sucralfate (1 g) will remain
adherent to the damaged mucosa for about 6
hours, so dosing at 6-hour intervals is
advised.
36. DRUG INTERACTIONS
Sucralfate binds the following drugs in the lumen of
the bowel: ciprofloxacin, digoxin,
ketoconazole , norfloxacin, phenytoin,
ranitidine , thyroxin , tetracycline ,
theophylline , and warfarin.
(The interactions with ciprofloxacin and norfloxacin
are considered the most significant) When these
drugs are given orally or via feeding tube,
sucralfate dosing should be separated by at least 2
hours to avoid any drug interactions.
37. ALUMINUM CONTENT:
The sucralfate molecule contains 8 aluminum
hydroxide moieties that are released when
sucralfate reacts with gastric acid.
The aluminum can bind phosphate in the
bowel, but hypophosphatemia is rare .
Nevertheless, sucralfate is not advised for
patients with persistent or severe
hypophosphatemia .
Sucralfate does not elevate plasma aluminum
levels, even with prolonged use .
38. Sulcrafate vs. Gastric Acid
Suppression
Sucralfate is appealing because it does not alter
gastric acidity, and should not create the increased
risk of infection that accompanies acid-suppressing
drugs.
Several clinical trials have compared sucralfate with
an acid-suppressing drug (ranitidine) for stress
ulcer prophylaxis, shows the combined results from
10 clinical trials involvin.
39. Clinically significant bleeding (defined earlier)
occurred less frequently with ranitidine,
while pneumonia occurred less frequently with
sucralfate.
When the incidence of bleeding and pneumonia
are combined (as shown in the center box),
there are fewer adverse events with sucralfate.
Although not shown, the mortality rate was the
same with both drugs.
40. There are two possible interpretations of the
results, based on the desired outcome.
If the desired result is fewer episodes of bleeding,
then ranitidine is superior to sucralfate.
However if the desired result is fewer adverse
events ( pneumonia), then sucralfate is
superior to ranitidine.
It seems that the goal of any preventive strategy
is fewer adverse events, in which case the
results would favor sucralfate over ranitidine
(i.e., gastric acid suppression) for prophylaxis
of stress ulcer bleeding.
41.
42. Gastric Acid Suppression and C.
difficile
One of the most compelling reasons for avoiding
gastric acid–suppressing drugs is the increased
risk of Clostridium difficile enterocolitis
associated with these drugs.
This has been reported in both outpatients and
inpatients , and is a greater risk with proton
pump inhibitors than with H2 blockers .
43. In fact, the increase in C. difficile enterocolitis
that has been observed in recent years
coincides with the increased use of proton
pump inhibitors in both outpatients and
inpatients.
It is very possible that the increasing incidence of
C. difficile enterocolitis in hospitalized patients
is not the result of increased antibiotic usage
(since antibiotics have always been overused),
but instead is a consequence of the escalating
use of gastric acid suppression for stress ulcer
prophylaxis .
44. Enteral Feeding
Enteral tube feedings exert a trophic effect on
the GI mucosa that helps to maintain the
structural and functional integrity of the
mucosal surface
Enteral feeding solutions also raise the pH in the
lumen of the stomach.
Both of these effects should protect against
stress ulcer bleeding.
45. The benefit of enteral tube feedings is revealed
in the combined results of three clinical
studies, which showed that the ability of H2
blockers to reduce stress ulcer bleeding was
lost when patients received a full regimen of
enteral tube feedings .
These results suggest that patients who receive
enteral tube feedings do not require any
further prophylactic measures for stress
ulcer bleeding.
46. I. Guideline Recommendations
1. In 1999, the first guideline from the
American Society of Health-System
Pharmacists was published (Am J Health Syst
Pharm1999;56:347-79).
The guideline recommended that institutions
decide on H2RAs , antacids, or sucralfate
according to safety profile, costs, and ease of
administration.
47. 2. In 2008, the Eastern Association
for the Surgery of Trauma published
a guideline recommending
cytoprotective agents, H2RAs, or
PPIs.
Antacids were not recommended.
3.In 2012, the Surviving Sepsis
Campaign guidelines commented on
SUP, recommending H2RAs or PPIs,
with PPIs as the preferred agent (Crit
48. 4. In 2014, the Danish Society of
Intensive Care Medicine and the
Danish Society of Anaesthesiology
and Intensive Care Medicine
published guidelines suggesting PPIs
as the preferred agent (Dan Med J
2014;61:C4811).
49. References
Steinberg KP. Stress-related mucosal disease in the critically ill patient: Risk factors
and strategies to prevent stress-related bleeding in the intensive care unit. Crit Care
Med 2002; 30(Suppl):S362–S364.
Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill
patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med
2002; 30(Suppl):S351–S355.
O’Brien PE. Gastric acidity: the gastric microvasculature and mucosal disease. In
Marston A, Bulkley GB, Fiddian-Green RG, Hagland UH, eds. Splanchnic Ischemia and
Multiple Organ Failure. St. Louis: C.V. Mosby, 1989:145–158.
Cook DJ, Fuller MB, Guyatt GH. Risk factors for gastrointestinal bleeding in critically
ill patients. N Engl J Med 1994; 330:377–381.
Daley RJ, Rebuck JA, Welage LS, et al. Prevention of stress ulceration: current trends in
critical care. Crit Care Med 2004; 32:2008–2013.
Ranitidine. AHFS Drug Information, 2011. Bethesda, MD: American Society of Health
System Pharmacists, 2011:2983–2990.
Famotidine. AHFS Drug Information, 2011. Bethesda, MD: American Society of
Health System Pharmacists, 2011:2977–2983.
50. Egred M. Clopidogrel and proton-pump inhibitor interaction. Br J Cardiol 2011.
Sucralfate. AHFS Drug Information, 2011. Bethesda, MD: American Society of Health
System Pharmacists, 2011:2996–2998.
Miller SJ, Simpson J. Medication–nutrient interactions: hypophosphatemia associated
with sucralfate in the intensive care unit. Nutr Clin Pract 1991; 6:199–201.
Tryba M, Kurz-Muller K, Donner B. Plasma aluminum concentrations in long-term
mechanically ventilated patients receiving stress ulcer prophylaxis with sucralfate.
Crit Care Med 1994; 22:1769–1773.
Lowe DO, Mamdani MM, Kopp A, et. al. Proton pump inhibitors and hospitalization
for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis
Dial S, Alrasadi K, Manoukian C, et. al. Risk of Clostridium-difficile diarrhea among
hospitalized patients prescribed proton pump inhibitors: cohort and case-control
studies. Canad Med Assoc J 2004; 171:33–38.
Aseri M, Schroeder T, Kramer J, Kackula R. Gastric acid suppression by proton pump
inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized
patients. Am J Gastroenterol 2008; 103:2308–2313.
Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new
millenium: a systematic review and meta-analysis. Crit Care Med 2010;. Maier RV, Mitchell D,
Gentiello L. Optimal therapy for stress gastritis. Ann Surg 1994;.
Rosenthal P, Thompson J, Singh M. Detection of occult blood in gastric juice. J Clin
• Gastroenterol 1984; 6:119.